Latest / Investor Exchange / HC Surgical Specialists: FY2025 Financial Performance and Strategic Acquisitions

Transcript

HC Surgical Specialists: FY2025 Financial Performance and Strategic Acquisitions · Investor Exchange

• 0:02
  Time for another Investor Exchange podcast. Here are your hosts, Matt and Sally.
• 0:08
  Imagine finding a shortcut to truly understanding a company's financial health,
• 0:12
  not just, you know, skimming the headlines, but really getting to the core of
• 0:16
  what made their year tick.
• 0:18
  Today, we're taking you on a deep dive into the latest financial results of
• 0:22
  HC Surgical Specialists Limited. Right.
• 0:26
  HCSS. For those maybe less familiar, HCSS is a Singapore-listed medical services group.
• 0:31
  They're mainly focused on providing specialized care, like endoscopic procedures,
• 0:36
  general surgery, that kind of thing.
• 0:38
  And they operate a pretty extensive network, right? About 18 clinics across Singapore.
• 0:44
  Exactly. So our mission for you today is really to unpack their FY 2025 financial statements.
• 0:49
  We're going to look closely at their performance, try to understand why certain
• 0:53
  numbers really jumped out, and maybe peek at the outlook too.
• 0:56
  And we're pulling this straight from their financial announcement.
• 0:59
  It's worth remembering these figures are, you know, still unaudited and unreviewed
• 1:02
  at this stage. Good point. OK, so let's unpack this then.
• 1:06
  When we first look at HG Surgical Specialist's full year results for FY 2025
• 1:09
  and compare them back to FY 2024, the revenue, well, it shows a slight increase,
• 1:15
  up by about 1.6 percent to $19.11 million.
• 1:21
  Which is steady, you know, positive movement. It is. But here's where it gets
• 1:25
  really interesting, almost startling, actually.
• 1:27
  The profit numbers. They are just...
• 1:30
  Well, they're off the charts. Yeah, that's what jumps out immediately.
• 1:33
  I mean, the sheer magnitude of the increase is fascinating.
• 1:36
  Profit before income tax for the full year, it surged by almost 74 percent,
• 1:40
  73.9 percent to be precise, reaching 8.80 million dollars. 74 percent.
• 1:45
  And if you look even deeper, the profit actually attributable to the owners,
• 1:49
  that saw an even more dramatic jump.
• 1:50
  We're talking 119.4 percent, hitting 8.44 million dollars. Wow.
• 1:55
  And that feeds directly into earnings per share, both basic and diluted.
• 1:58
  117% increase there, from 2.53 cents up to 5.49 cents. It's really a remarkable
• 2:04
  turnaround, especially if you zone in on the second half of the year.
• 2:06
  Operating profit after tax there soared by over, get this, 1,300%.
• 2:10
  1,300%. Okay, that's an astonishing leap in profitability.
• 2:15
  Yeah. So what does this all mean? What were the specific factors driving this,
• 2:20
  well, frankly, incredible performance?
• 2:22
  It can't just be more patience, right? No, not entirely. I mean,
• 2:27
  a key driver for that modest revenue increase was the contribution from a new
• 2:31
  subsidiary they acquired during the year.
• 2:33
  So, yes, part of it is growth through acquisition. OK, that makes sense.
• 2:36
  But beyond the core services, other income also saw a bit of an increase.
• 2:40
  This came mainly from things like higher government grants, some compensation
• 2:44
  related to a non-controlling interest in GMH, and also an increase in consultancy fee income.
• 2:50
  Though, you know, to be fair, some of that was offset a bit by lower dividend
• 2:54
  income from their financial investments.
• 2:57
  Interesting. So grants, compensation, consultancy.
• 3:00
  But looking at the sheer size of that profit jump, a significant chunk seems
• 3:04
  to come from these fair value gains on financial incidents.
• 3:07
  What exactly are these derivative financial instruments and financial assets
• 3:11
  at FBPPL, and how did they suddenly become such a profit powerhouse this year?
• 3:15
  Right. This is crucial to understanding the nature of the gains.
• 3:18
  So that substantial fair value gain, S$1.46 million, on derivative financial
• 3:24
  instruments, that's a huge swing from a $6.62 million loss last year. Big swing.
• 3:30
  Huge. And it primarily stemmed from the remeasurement of a forward purchase contract.
• 3:35
  Basically, an agreement related to buying more of an associate company down the line.
• 3:39
  Think of it like valuing an option they held. Ah, okay. So not cash in hand,
• 3:43
  but the value of the agreement itself went up.
• 3:45
  Precisely. It's an accounting gain based on changing valuations.
• 3:48
  And similarly, there was a fair value gain of $6.70 million on what's called
• 3:54
  financial assets at fair value through profit or loss or FVTPL.
• 3:58
  Again, sounds complex, but it's largely due to an increase in the share prices
• 4:02
  of companies they invest in, like Mednex Limited and HSN Healthcare.
• 4:05
  But investments in other listed companies.
• 4:07
  Exactly, though it was tempered a bit by decreases in others they hold,
• 4:11
  like Singapore pain care holdings and Aox and Q&M Dental.
• 4:15
  But the key takeaway here is these big gains aren't directly from their core medical services.
• 4:21
  They're from strategic financial investments and these contractual arrangements.
• 4:25
  Okay, so it really sounds like a blend then.
• 4:27
  Strategic financial moves, definitely, but also some operational improvements.
• 4:31
  Were there any notable shifts on the expense side that helped boost that bottom line? There were, yeah.
• 4:38
  While some expenses did increase, which you'd expect with growth,
• 4:41
  like inventories, consumables, surgery expenses went up by $0.28 million,
• 4:46
  consistent with the new subsidiary and higher revenue.
• 4:49
  Makes sense. And employee benefits also rose, mainly due to more staff and higher
• 4:54
  locum doctor fees for that new subsidiary, MDS.
• 4:58
  Depreciation went up too, mostly from renewing clinic leases.
• 5:01
  However, they also saw some significant positives on the expense side.
• 5:04
  There was a reversal of loss allowance for receivables, basically,
• 5:07
  money they previously thought they wouldn't collect came through or the provision wasn't needed anymore.
• 5:12
  That added about $0.24 million back.
• 5:16
  Nice little recovery there. Definitely. And other expenses actually decreased
• 5:20
  by several $0.43 million.
• 5:22
  This was helped by reversing a prior impairment loss on some equipment and also
• 5:27
  lower professional fees.
• 5:29
  So some good cost management and perhaps some recovery of value there too.
• 5:33
  Got it. And you mentioned investments earlier.
• 5:35
  The report talks about a loss arising from deemed disposal in an associate,
• 5:39
  but then there's also this positive swing in the share of results of associates.
• 5:44
  How do those pieces fit together? Sounds a bit contradictory at first glance.
• 5:48
  Yeah, it can seem that way.
• 5:49
  That several $0.21 million loss from the deemed disposal that relates specifically
• 5:55
  to the remeasurement of HCSS's original stake in MDS right when it became a subsidiary.
• 6:01
  It's more of an accounting technicality when control changes,
• 6:04
  not really a reflection of poor performance. Okay, a paper adjustment, essentially.
• 6:07
  Pretty much. But if you look at the bigger picture, their share results from
• 6:10
  all associates actually swung positive.
• 6:12
  It went from a loss of $88,000 last year to a profit of $0.43 million this year. Big improvement. Yeah.
• 6:19
  Largely driven by profits coming from TPL and MDS itself after the acquisition.
• 6:25
  Plus, their share of results from a joint venture also added a positive second
• 6:29
  row $0.35 million in profit. So their investments are contributing nicely overall now.
• 6:34
  And it seems like they caught a break on finance costs and income tax,
• 6:37
  too. Those look like big wins. Absolutely.
• 6:39
  Finance costs dropped by $0.24 million.
• 6:42
  That's mainly because they finished paying off some deferred considerations, basically.
• 6:46
  Installment payments from prior acquisitions. Less debt means less interest.
• 6:50
  Always good. And the income tax expense saw a massive decrease, set for $1.10 lower.
• 6:56
  Now, this was mainly due to finding they'd overprovided for tax in previous
• 7:00
  years, plus they benefited from a government tax rebate.
• 7:03
  Ah, so maybe not entirely repeatable. Exactly.
• 7:06
  The lower finance costs could stick if debt stays down, but that big tax benefit
• 7:10
  is likely more of a one-off boost to this year's net profit.
• 7:13
  Still, a very significant positive impact for FY 2025.
• 7:16
  Okay, that gives us a really comprehensive look at the profit and loss side. Okay.
• 7:20
  Beyond those big overall figures, were there any other interesting changes in
• 7:26
  specific assets or liabilities that kind of paint the picture of what they were doing? Sure.
• 7:31
  Plant and equipment increased. That was driven partly by new additions,
• 7:34
  but also that reversal of prior impairment losses we mentioned,
• 7:38
  basically saying some existing assets are worth more than previously thought.
• 7:43
  Intangible assets, which is mostly goodwill in their case, increased because
• 7:47
  of the acquisition of MDS.
• 7:49
  That reflects the premium paid for that business. And on the other side,
• 7:53
  trade and other payables saw a really substantial decrease, down S3.18 million dollars.
• 7:59
  That's largely due to making those deferred consideration payments for past
• 8:03
  acquisitions, settling old bills.
• 8:05
  And you also see movements in things like capital reserve and other reserves,
• 8:09
  which tie back to those strategic moves, like acquiring the non-controlling
• 8:13
  interests and subsidiaries like GMH, HCMC, and MDS, and then sorting out the
• 8:18
  related financial liabilities. Yeah.
• 8:20
  So, yeah, the balance sheet really shows a company actively managing its capital
• 8:23
  structure, paying down debts and integrating those recent acquisitions.
• 8:27
  It's one thing to see profits on paper. We always say this, but cash flow tells
• 8:31
  the real story, doesn't it? The actual money coming in and going out. Yeah.
• 8:35
  How did all this financial activity impact HCSS's actual cash position during the year? Yeah.
• 8:41
  Cash is king, right? So net cash from operating activities actually increased
• 8:45
  nicely by $0.93 million, reaching $7.23 million.
• 8:50
  That was largely thanks to higher operating receipts. So the core business is
• 8:54
  generating strong cash. That's a good sign. Healthy operations. Definitely.
• 8:58
  However, they shifted quite dramatically in investing activities.
• 9:01
  In FY 2024, they actually generated cash from investing.
• 9:04
  In FY 2025, they used cash and net outflow of $7.45 million.
• 9:09
  Okay. What were they investing in? Primarily, it was making those significant
• 9:12
  deferred consideration payments related to the Tito PL acquisition and also
• 9:16
  buying more plant and equipment.
• 9:18
  So investing back into the business and settling past deals.
• 9:21
  Got it. And what about financing activities? Paying down debt,
• 9:24
  dividends? What does that look like? That's where a lot of cash went out.
• 9:28
  Cash used in financing activities increased quite a bit to $9.06 million.
• 9:33
  This tells us they were really busy on this front. Doing what specifically?
• 9:37
  Well, acquiring those non-controlling interests and subsidiaries, GMH, HCMC, MDS.
• 9:43
  Making large deferred payments for another acquisition, JLES,
• 9:47
  paying out increased dividends both to their own shareholders and to the non-controlling
• 9:51
  interests and subsidiaries.
• 9:52
  And as we mentioned, Fulier paying that bank borrowing and also paying down lease liabilities.
• 9:57
  So a lot of outflows, but for strategic reasons, acquisitions,
• 10:00
  debt reduction, shareholder returns. Exactly.
• 10:03
  So while the operating cash flow was strong and healthy, the company made a
• 10:06
  conscious decision to deploy a significant amount of that cash strategically.
• 10:10
  The net result was an overall decrease in their cash and cash equivalents for the year.
• 10:15
  They ended with $5.09 million in cash. They definitely put their money to work. Right.
• 10:23
  OK, so we've looked back at what was clearly a very dynamic,
• 10:27
  transformative financial year.
• 10:29
  Now let's turn our gaze forward. What's the outlook for HC's surgical specialists,
• 10:34
  especially thinking about the broader economic climate?
• 10:36
  Well, the company itself acknowledges there are external factors to watch.
• 10:40
  Their financial announcement actually points to a specific news article from
• 10:43
  late July 2025, which mentions potential U.S.
• 10:47
  Tariffs 10 percent on Singapore goods.
• 10:49
  Tariffs. Always a concern. Right. And while the announcement quotes Singapore's
• 10:53
  prime minister, Lawrence Wong, as noting the country can live with that baseline
• 10:57
  rate, HCSS itself acknowledges that Trump's tariffs will continue to affect
• 11:01
  the economic stability of Singapore as well as globally.
• 11:04
  So they're aware of potential turbulence.
• 11:07
  How are they planning to navigate these potential headwinds then?
• 11:10
  What's their stated strategy? It seems pretty clear and, frankly, sensible.
• 11:14
  Their strategy is to focus on the local and regional market.
• 11:18
  They state, quite directly, they will continue to stay vigilant and focus on
• 11:22
  driving revenue and improving operating efficiencies in a bid to contain costs.
• 11:27
  So control what you can control.
• 11:29
  Focus inward. Exactly. It suggests a cautious but proactive approach.
• 11:35
  Keep an eye on the external stuff, but really double down on running the core
• 11:38
  business efficiently and managing costs effectively within their primary market,
• 11:43
  especially given that potential global uncertainty.
• 11:45
  Makes sense. Now, for many of our listeners, probably a key takeaway from any
• 11:49
  company's performance is what it means for them directly as investors.
• 11:53
  So after this year of impressive profits, what's the story with dividends?
• 11:56
  It's good news on that front.
• 11:58
  Reflecting those higher net profits, the directors are recommending a significantly
• 12:02
  increased final dividend for FY 2025.
• 12:05
  That's 1.18 cents per ordinary share. Okay. And wasn't there an interim dividend already? Correct.
• 12:12
  They already paid out 0.80 cents as an interim dividend.
• 12:15
  So this brings the total annual dividend for FY 2025 to 1.98 cents per share.
• 12:21
  How does that compare to last year?
• 12:23
  It's a notable increase. Last year, FY 2024, the total was 1.40 zero cents per share.
• 12:29
  So going up to 1.98 cents is a healthy bump.
• 12:31
  It definitely shows confidence from the board in the company's performance and
• 12:34
  its prospects, and it's a direct reward back to shareholders.
• 12:38
  What a journey through the financials of HC Surgical Specialists Limited.
• 12:42
  I mean, it's really clear that FY 2025 wasn't just another year.
• 12:45
  It was a year of quite remarkable transformation and growth.
• 12:48
  Absolutely. Driven, yes, by their core medical services, but maybe even more
• 12:52
  so by some really shrewd financial management, those strategic acquisitions
• 12:56
  and putting their cash to work, paying down debt and rewarding shareholders. Indeed.
• 13:01
  I think this deep dive really highlights how even in a sector like health care,
• 13:05
  which you might think of as relatively stable, a company can achieve pretty explosive growth.
• 13:10
  It takes that combination, operational efficiency, yes, but also smart strategic
• 13:14
  investments and, interestingly here, the clever use of financial instruments.
• 13:19
  Yeah, the financial instruments part was fascinating. It was.
• 13:22
  And you know what really struck me, thinking beyond just these numbers, is exactly that point.
• 13:27
  How a company in what seems like a stable, predictable industry medical services
• 13:32
  can leverage things like complex financial derivatives and strategic M&A to
• 13:37
  generate such, well, explosive profit growth in a single year.
• 13:41
  Right. It kind of makes you wonder, doesn't it, what other seemingly safe or
• 13:45
  boring sectors might be hiding these kinds of financial gymnastics.
• 13:49
  Setting up potentially big gains in the future, something to think about.